| | |
Clinical Outcomes
|
|
CVD-Related Hospitalization |
Non-CVD-Related Hospitalization |
|
HR |
95% CI |
HR |
95% CI |
| Baseline Cox model of hospitalization risk (n=272 899) |
| Timely secondary prevention |
0.67a |
[0.66-0.69) |
1.00 |
(0.98-1.01) |
| Adding baseline LDL levels for subpopulation (n=49 224) |
| Timely secondary prevention |
0.68a |
(0.64-0.72) |
1.05a |
(1.01-1.08) |
| 101-130 mg/dL (vs <101 mg/dL) |
1.02 |
(0.96-1.08) |
0.91a |
(0.88-0.94) |
| 131-160 mg/dL (vs <101 mg/dL) |
1.16a |
(1.08-1.25) |
0.87a |
(0.83-0.92) |
| >160 mg/dL(vs <101) |
1.45a |
(1.31-1.60) |
0.95 |
(0.88-1.02) |
| Treatment effect (relative risk) in each LDL-C level group for subpopulation [n=49 224] |
| LDL <101 mg/dL |
0.66a |
(0.60-0.72) |
1.04 |
(0.98-1.10) |
| Change in absolute risk |
-0.55% |
|
|
|
| LDL 101-130 mg/dL |
0.74a |
(0.67-0.82) |
1.12a |
(1.06-1.19) |
| Change in absolute risk |
-0.92% |
|
|
|
| LDL 131-160 mg/dL |
0.65a |
(0.57-0.73) |
0.97 |
(0.89-1.05) |
| Change in absolute risk |
-1.14% |
|
|
|
| LDL >160 mg/dL |
0.61a |
(0.51-0.73) |
0.94 |
(0.83-1.07) |
| Change in absolute risk |
-3.21% |
|
|
|
| All-cause cost outcomes 1 year post |
|
Medical+Inpatient Costs |
Drug Costs |
Total Costs |
|
Effect in US $ |
95% CI |
Effect in US $ |
95% CI |
Effect in US $ |
95% CI |
| GLM model (n=272 899) |
| Secondary prevention |
147 |
(-63 356) |
272a |
(246 297) |
509a |
(293 726) |